目的 在《生物类似药研发与评价技术指导原则》新出台的背景下,就生物类似药药学研究存在的一些挑战进行分析探讨。方法 从原研药的研究、细胞表达系统和工艺、分析方法和质量控制参数、免疫学特性以及制剂配方和包材等方面提出生物类似药药学开发中,面临的一些挑战和难题。结果与结论 通过对上述问题的分析,提出生物类似药药学研究的建议。同时,建议研发企业充分考虑开发生物类似药面临的风险和挑战,研发出与原研药质量一致的产品,满足国内公众用药需求的同时,实现与国际要求的接轨。
Abstract
OBJECTIVE To propose some challenges of the pharmaceutical studies on biosimilars. METHODS Some key points should be considered, including the investigation of original biologics, cell expression system and manufacture process, analytical methods and quality attributes, immunological properties, and formulation and primary packaging materials,when a biosimilar was developed. RESULTS AND CONCLUSION Some suggestions we proposed on the pharmaceutical evaluation of biosimilars. Meanwhile, it is suggested that sponsors should be aware of the challenges and difficulties of developing biosimilars and develop biosimilars with equivalent quality to the original products, which not only meets the need of the public for the medicines, but also adapts to the international requirements.
关键词
生物类似药 /
质量研究 /
研发 /
评价
{{custom_keyword}} /
Key words
biosimilar /
quality study /
development /
evaluation
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] EMA. Guideline on similar biological medicinal products[S]. 2006.[2] Health Canada. Guidance for sponsors: Information and submission requirements for subsequent entry biologics[S]. 2010.[3] US legislation H. R. 1548: Pathway for Biosimilars Act[S]. 2011.[4] WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs)[S]. 2010.[5] SENSABAUGH S M. Requirements for biosimilars and interchangeable biological drugs in the United States[J]. Drug Inf J, 2011,45(2):155-162. [6] PAUL J D. Biologicals and biosimilars: a review of the science and its implications[J]. Generics and Biosimilars Initiative Journal, 2012,1(1):13-16. [7] SEKHON B S, SALUJA V. Biosimilars: an overview[J]. Biosimilars,2011,1:1-11. [8] CHIRINO A J, MIRE-SLUIS A. Characterizing biological products and assessing comparability following manufacturing changes[J]. Nat Biotechnol,2006,22:1383-1391. [9] Amgen. Amgen′s adalimumab biosimilar hits the target of Phase III study[N/OL]. Biosimilar News,[2014-10-12]. http://www. biosimilarnews. com/amgens-adalimumab-biosimilar-hits-the-target-of-phase-iii-study. [10] Oncobiologics. Oncobiologics launches Phase I clinical trial for Humira biosimilar[N/OL]. Biosimilar News,[2014-6-13]. http://www. biosimilarnews. com/oncobiologics-launches-phase-i-clinical-trial-for-humira-biosimilar. [11] PM Live . Boehringer lines up biosimilars of major biopharmaceuticals[N/OL]. Biosimilar News. [2014-4-18]. http://www. biosimilarnews. com/boehringer-lines-up-biosimilars-of-major-biopharmaceuticals. [12] Niederwieser D and Stephan Schmitz. Biosimilar agents in oncology/haematology: from approval to practice[J]. Eur J Haematol, 2011,86(2):277-288. [13] Teva halts the Phase III studies of biosimilar rituximab[N/OL]. Biosimilar News. [2012-10-05]. http://www. biosimilarnews. com/teva-halts-the-phase-iii-studies-of-biosimilar-rituximab. [14] Samsung haltsbiosimilar rituximab trials on regulatory concern[N/OL]. [2012-10-24]. http://www.in-pharmatechnologist.com/Regulatory-Safety/Samsung-halts-biosimilar-rituximab-trial-on-regulatory-concerns? nocount. [15] CROMMELIN D J, STORM G, VERRIJK R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs[J]. Int J Pharm, 2003, 266(1-2):3-16. [16] CROMMELIN D, BERMEJO T, BISSIG M, et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals[J]. Eur J Hosp Pharm Sci, 2005, 11(1):11-17. [17] DECLERCK P J. Biotherapeutics in the era of biosimilars: what really matters is patient safety[J]. Drug Saf, 2007, 30:1087-1092. [18] SUROWY T, CHENG Z J,GARVIN D, et al. Low Variability ADCC Bioassay Novel NFAT Reporter Bioassay for Fc Effector Function [N/OL]. Assay Tutorials. [2012-04-01]. http: //www.genengnews.com/gen-articles/low-variability-adcc-bioassay/4055/[19] EMA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins[S]. 2007. [20] SCHELLEKENS H, CASADEVALL N. Immunogenicity of recombinant human proteins: causes and consequences[J]. J Neurol, 2004,2(9):114-119. [21] U. S. Patents 8,216,583 and 8,420,081[P]. WO2014039903A2.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项“重大新药创制”课题资助项目(项目编号2015ZX09501008)
{{custom_fund}}
PDF(512 KB)
